Evidence map›Paper›PMID 38315678›Full record

Trial reportThe international journal of neuropsychopharmacology2024

Ketone Supplementation Dampens Subjective and Objective Responses to Alcohol: Evidence From a Preclinical Rat Study and a Randomized, Cross-Over Trial in Healthy Volunteers.

Xinyi Li, Zhenhao Shi, Dustin R Todaro, Timothy Pond, Juliana I Byanyima, Sianneh A Vesslee, Rishika Reddy, Ravi Prakash Reddy Nanga, Gabriel Kass, Vijay Ramchandani and 4 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xinyi LiCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-3136-4811
Zhenhao ShiCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Dustin R TodaroCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Timothy PondCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Juliana I ByanyimaCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Sianneh A VessleeCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Rishika ReddyCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Ravi Prakash Reddy NangaUniversity of Pennsylvania Perelman School of Medicine, Department of Radiology, Philadelphia, Pennsylvania, USA.
Gabriel KassCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Vijay RamchandaniNational Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
Henry R KranzlerCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-1018-0450
Janaina C M VendruscoloNational Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
Leandro F VendruscoloNational Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
Corinde E WiersCenter for Studies of Addiction, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-2934-8794
University of Pennsylvania · USNational Institutes of Health · US

Funding

Alcohol Pharmacokinetics and Pharmacodynamics in HumansZIAAA000466 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI RAMCHANDANI, VIJAY ARJUN · 2009 to 2025
$31.2M
T32 Translational Addiction Research Fellowship ProgramT32DA028874 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI Julie A Blendy, Anna Rose Childress · 2010 to 2026
$5.0M
Multivariate Modeling of the Neural Mechanisms of Treatment Response in Opioid AddictionK01DA051709 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SHI, ZHENHAO · 2021 to 2025
$916k
Ketone ester intervention in alcohol use disorderR00AA026892 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI WIERS, CORINDE E · 2020 to 2022
$747k
Modulation of alcohol sensitivity and alcohol tolerance by exogenous ketones in humansR21AA031088 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI NANGA, RAVI PRAKASH REDDY, WIERS, CORINDE E · 2024 to 2025
$421k
NIAAA NIH HHS R00 AA026892NIAAA NIH HHS R21 AA031088NIDA NIH HHS K01 DA051709NIDA NIH HHS T32 DA028874NIH HHS T32DA028874-11
6 · The paper itself

Abstract

backgroundPrevious preclinical and human studies have shown that a high-fat ketogenic diet and ketone supplements (KS) are efficacious in reducing alcohol craving, alcohol consumption, and signs of alcohol withdrawal. However, the effects of KS on alcohol sensitivity are unknown.

methodsIn this single-blind, cross-over study, 10 healthy participants (3 females) were administered a single, oral dose of a KS (25 g of ketones from D-β-hydroxybutyric acid and R-1,3-butanediol) or placebo 30 minutes before an oral alcohol dose (0.25 g/kg for women; 0.31 g/kg for men). Assessments of breath alcohol concentration and blood alcohol levels (BAL) and responses on the Drug Effect Questionnaire were repeatedly obtained over 180 minutes after alcohol consumption. In a parallel preclinical study, 8 Wistar rats (4 females) received an oral gavage of KS (0.42 g ketones/kg), water, or the sweetener allulose (0.58 g/kg) followed 15 minutes later by an oral alcohol dose (0.8 g/kg). BAL was monitored for 240 minutes after alcohol exposure.

resultsIn humans, the intake of KS before alcohol significantly blunted breath alcohol concentration and BAL, reduced ratings of alcohol liking and wanting more, and increased disliking for alcohol. In rats, KS reduced BAL more than either allulose or water.

conclusionKS altered physiological and subjective responses to alcohol in both humans and rats, and the effects were likely not mediated by the sweetener allulose present in the KS drink. Therefore, KS could potentially reduce the intoxicating effects of alcohol.

Indexed as

AlcoholismSubstance Withdrawal SyndromeAnimalsBlood Alcohol ContentCross-Over StudiesDietary SupplementsEthanolFemaleHealthy VolunteersHumansKetonesMaleRatsRats, WistarSingle-Blind MethodSweetening AgentsBlood Alcohol ContentEthanolKetonesSweetening AgentsWateralcohol intoxicationalcohol sensitivityalcohol use disorderKetone supplementsnutritional ketosis

Identifiers

PMID38315678
PMCPMC10901540
OpenAlexW4391529471

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.